Top Stories
BMS will help build new Bunsen functions for chemical exploration and synthesis planning, extending a partnership that began in 2020 with a five-target drug discovery deal worth up to $2.7 billion.
A study has found PRISM2 matched or beat three specialist products without separate training for each task.
CEO Orr Inbar said clinical development still relies on "running trials, waiting for results, and adjusting at significant cost and risk."
The AI biotech secured ex-China rights to Alphamab's TROP2/HER3 ADC in a deal worth up to $2.2 billion and partnered with AstraZeneca on a breast cancer PROTAC programme.
The alliance pairs enzymatic peptide engineering with physics-based AI modelling.
Conference News
University of Colorado Anschutz-led study shows automated oxygen system increases time in target oxygen range and reduces clinician workload compared with standard careAURORA, Colo., Aug. 3, 2026 /PRN...
Following the introduction of Invenia™ ABUS Prime at the Society of Breast Imaging Annual Symposium, the installation at BeSound in Los Angeles marks one of the first in the U.S., expanding access to ...
Company will present two scientific posters examining the operational and readiness applications of its tAN® platform, marking a key step in Spark's expansion into the military-ready and first respond...
Second Quarter Revenue Growth of 52% to $132 MillionRaises 2026 Revenue Guidance to $490 Million to $500 Million and Raises 2026 AEBITDA Guidance to $66 Million to $78 MillionBRISBANE, Calif.--(BUSINE...
Second quarter 2026 revenue growth of 44% driven by strong performance in Oncology and ScreeningRaises 2026 revenue guidance to $1.34 to $1.36 billion, representing growth of 36% to 38%PALO ALTO, Cali...
